Beta-galactose modified chlorambucil-BODIPY combined antitumor prodrug as well as preparation method and application thereof

The invention discloses a beta-galactose modified chlorambucil-BODIPY (boron dipyrromethene) combined antitumor prodrug as well as preparation and application of the beta-galactose modified chlorambucil-BODIPY combined antitumor prodrug. Due to introduction of beta-galactose, the prodrug can be rapidly and selectively taken in by tumor cells, glucosidic bonds in molecules of the prodrug can be cut off by beta-galactosidase overexpressed in the tumor cells, an original drug chlorambucil and a photosensitizer BODIPY are released through a continuous and rapid intramolecular conversion reaction, and under illumination, the prodrug can be rapidly and selectively taken in the tumor cells. The selective chemotherapy-photodynamic combined treatment is realized. Human-derived ovarian cancer cells A2780, mouse-derived ovarian cancer cells ID8 and mouse embryo fibroblasts 3T3 are used as tested cell strains, and the prodrug is verified to have the characteristic of actively targeting tumor cells and excellent combined